These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38243896)

  • 1. Rationally Designed Cu(I) Ligand to Prevent CuAβ-Generated ROS Production in the Alzheimer's Disease Context.
    Rulmont C; Stigliani JL; Hureau C; Esmieu C
    Inorg Chem; 2024 Feb; 63(5):2340-2351. PubMed ID: 38243896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ability of Azathiacyclen Ligands To Stop Cu(Aβ)-Induced Production of Reactive Oxygen Species: [3N1S] Is the Right Donor Set.
    Malikidogo KP; Drommi M; Atrián-Blasco E; Hormann J; Kulak N; Esmieu C; Hureau C
    Chemistry; 2023 Mar; 29(14):e202203667. PubMed ID: 36606721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Water-Soluble Peptoid Chelator that Can Remove Cu
    Behar AE; Sabater L; Baskin M; Hureau C; Maayan G
    Angew Chem Int Ed Engl; 2021 Nov; 60(46):24588-24597. PubMed ID: 34510664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unexpected Trends in Copper Removal from Aβ Peptide: When Less Ligand Is Better and Zn Helps.
    Esmieu C; Balderrama-Martínez-Sotomayor R; Conte-Daban A; Iranzo O; Hureau C
    Inorg Chem; 2021 Jan; 60(2):1248-1256. PubMed ID: 33400522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new water-soluble Cu(II) chelator that retrieves Cu from Cu(amyloid-β) species, stops associated ROS production and prevents Cu(II)-induced Aβ aggregation.
    Noël S; Perez F; Pedersen JT; Alies B; Ladeira S; Sayen S; Guillon E; Gras E; Hureau C
    J Inorg Biochem; 2012 Dec; 117():322-5. PubMed ID: 22819647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Trishistidine Pseudopeptide with Ability to Remove Both Cu
    Conte-Daban A; Boff B; Candido Matias A; Aparicio CNM; Gateau C; Lebrun C; Cerchiaro G; Kieffer I; Sayen S; Guillon E; Delangle P; Hureau C
    Chemistry; 2017 Dec; 23(67):17078-17088. PubMed ID: 28846165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational Design of a Cu Chelator That Mitigates Cu-Induced ROS Production by Amyloid Beta.
    Mitra S; Talukdar K; Prasad P; Misra SK; Khan S; Sharp JS; Jurss JW; Chakraborty S
    Chembiochem; 2022 Feb; 23(4):e202100485. PubMed ID: 34878720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How Zn can impede Cu detoxification by chelating agents in Alzheimer's disease: a proof-of-concept study.
    Conte-Daban A; Day A; Faller P; Hureau C
    Dalton Trans; 2016 Oct; 45(39):15671-15678. PubMed ID: 27711738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why the Ala-His-His Peptide Is an Appropriate Scaffold to Remove and Redox Silence Copper Ions from the Alzheimer's-Related Aβ Peptide.
    Gonzalez P; Sabater L; Mathieu E; Faller P; Hureau C
    Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methionine does not reduce Cu(II)-beta-amyloid!--rectification of the roles of methionine-35 and reducing agents in metal-centered oxidation chemistry of Cu(II)-beta-amyloid.
    da Silva GF; Lykourinou V; Angerhofer A; Ming LJ
    Biochim Biophys Acta; 2009 Jan; 1792(1):49-55. PubMed ID: 19061952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybrid Bis-Histidine Phenanthroline-Based Ligands to Lessen Aβ-Bound Cu ROS Production: An Illustration of Cu(I) Significance.
    Drommi M; Rulmont C; Esmieu C; Hureau C
    Molecules; 2021 Dec; 26(24):. PubMed ID: 34946712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Keggin-type polyoxometalates as Cu(II) chelators in the context of Alzheimer's disease.
    Atrián-Blasco E; de Cremoux L; Lin X; Mitchell-Heggs R; Sabater L; Blanchard S; Hureau C
    Chem Commun (Camb); 2022 Feb; 58(14):2367-2370. PubMed ID: 35080532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The redox chemistry of the Alzheimer's disease amyloid beta peptide.
    Smith DG; Cappai R; Barnham KJ
    Biochim Biophys Acta; 2007 Aug; 1768(8):1976-90. PubMed ID: 17433250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Power of Dopamine: Multifunctional Compound Assisted Conversion of the Most Risk Factor into Therapeutics of Alzheimer's Disease.
    Gharai PK; Khan J; Pradhan K; Mallesh R; Garg S; Arshi MU; Barman S; Ghosh S
    ACS Chem Neurosci; 2024 Jul; 15(13):2470-2483. PubMed ID: 38874606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copper(I) Chelators for Alzheimer's Disease.
    Opare SKA; Rauk A
    J Phys Chem B; 2017 Dec; 121(50):11304-11310. PubMed ID: 29172520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and bio-activities of bifunctional tetrahydrosalen Cu (II) chelators with potential efficacy in Alzheimer's disease therapy.
    Sun B; Jiang H
    J Inorg Biochem; 2024 Oct; 259():112636. PubMed ID: 38943843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copper-Targeting Approaches in Alzheimer's Disease: How To Improve the Fallouts Obtained from in Vitro Studies.
    Esmieu C; Guettas D; Conte-Daban A; Sabater L; Faller P; Hureau C
    Inorg Chem; 2019 Oct; 58(20):13509-13527. PubMed ID: 31247877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Aβ peptide aggregation by ruthenium(II) polypyridyl complexes through copper chelation.
    Peng YB; Tao C; Tan CP; Zhao P
    J Inorg Biochem; 2021 Nov; 224():111591. PubMed ID: 34450410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of copper(II) specific pyridine containing ligands: Potential metallophores for Alzheimer's disease therapy.
    Jakusch T; Hassoon AA; Kiss T
    J Inorg Biochem; 2022 Mar; 228():111692. PubMed ID: 34990971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copper and heme-mediated Abeta toxicity: redox chemistry, Abeta oxidations and anti-ROS compounds.
    Chassaing S; Collin F; Dorlet P; Gout J; Hureau C; Faller P
    Curr Top Med Chem; 2012; 12(22):2573-95. PubMed ID: 23339309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.